ProPharma has inaugurated a new office in Hyderabad, India, to expand its pharmaceutical consulting, regulatory, and outsourcing support for Asia-Pacific drug developers and manufacturers.

The European Medicines Agency has published a revised EU guideline on stability testing for post‑approval variations, raising and clarifying CMC data expectations for marketing authorisation holders operating in Europe.

New industry analysis highlights Asia’s increasing dependence on China for pharmaceutical active ingredients, with implications for manufacturing resilience, sourcing strategy, and regulatory risk management across the region.

The European Union has agreed a new pharmaceutical framework that streamlines regulation and reinforces supply security mechanisms, reshaping the operating environment for drug manufacturers across Europe.

Pfizer has signed a licensing agreement worth up to US$2.1 billion with Fosun Pharma unit Yao Pharma for an oral GLP-1 obesity drug program, underscoring China’s rising role in global metabolic drug innovation and cross-border pharma partnering.

The European Commission has approved a €47 million German State aid package to support Vetter Pharma’s expansion of sterile injectable manufacturing capacity, reinforcing Europe’s contract manufacturing and pharmaceutical supply chain capabilities.

Agilent Technologies and Monash University Malaysia are creating a new biodiscovery hub that will expand access to advanced analytical platforms for pharmaceutical and biotech R&D across Malaysia and the wider Asia-Pacific region.

The European Commission has approved Roche’s Gazyva/Gazyvaro for lupus nephritis, a move that bolsters the EU biologics market and has strategic implications for autoimmune portfolios, manufacturing, and supply across Europe.

Singapore-based AI-for-science startup ChemLex has raised $45 million to establish a fully autonomous, AI-driven drug discovery lab and global R&D headquarters, strengthening Asia’s life sciences innovation and outsourcing ecosystem.

The European Medicines Agency has published a new Direct Healthcare Professional Communication (DHPC) for Remsima (infliximab), requiring EU market authorisation holders and hospital stakeholders to review safety, risk‑minimisation and pharmacovigilance measures for this biosimilar across European markets.